Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer.
N Engl J Med 2020;383:813-24.
2.) Wirth LJ, Sherman E, Robinson B, et al.:
Efficacy of selpercatinib in RET-altered thyroid cancers.
N Engl J Med 2020;383: 825-35.
3. Subbiah V, Wolf J, Konda B, et al.:
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Lancet Oncol 2022;23:1261-73.
4.) Mulligan L:
Selective RET Kinase Inhibitors and Lung Cancer. Science behind the study.
NEJM 389;20: 1913-1916
5.) Araghi M, Mannani R, Heidarnejad Maleki A, et al.:
Recent advances in non-small cell lung cancer targeted therapy; an up-date review.
Cancer Cell Int 2023;23:162
6.) Zhou C, Solomon B, Loong HH, et al.:
First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC.
N Engl J Med 2023;389:1839-50.
Teil von
